Late Breaking Abstract- Comparative Effectiveness of Anti-IL5/5R Versus Anti-IgE in Patients Eligible for Both (FIRE)

被引：1
|
作者：
Ali, Nasloon [1 ]
Lyu, Juntao [1 ]
Newell, Anthony [1 ]
Sadatsafavi, Mohsen [2 ]
Tran, Trung N. [3 ]
Price, David B. [1 ,4 ]
机构：
[1] Observat & Pragmat Res Inst, Singapore, Singapore
[2] Univ British Columbia, Fac Pharmaceut Sci, Resp Evaluat Sci Program, Vancouver, BC, Canada
[3] AstraZeneca, Gaithersburg, MD USA
[4] Univ Aberdeen, Div Appl Hlth Sci, Ctr Acad Primary Care, Aberdeen, Scotland
来源：
EUROPEAN RESPIRATORY JOURNAL | 2021年 / 58卷
关键词：
Treatments; Severe asthma; Asthma; -; management;
D O I：
10.1183/13993003.congress-2021.PA1113
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
PA1113
引用
收藏
页数：2
相关论文
共 45 条
  • [1] Comparative effectiveness of Anti-IL5 and Anti-IgE biologic classes in patients with severe asthma eligible for both
    Pfeffer, Paul E.
    Ali, Nasloon
    Murray, Ruth
    Ulrik., Charlotte
    Tran, Trung N.
    Maspero, Jorge
    Peters, Matthew
    Christoff, George C.
    Sadatsafavi, Mohsen
    Torres-Duque, Carlos A.
    Altraja, Alan
    Lehtimaki, Lauri
    Papadopoulos, Nikolaos G.
    Salvi, Sundeep
    Costello, Richard W.
    Cushen, Breda
    Heffler, Enrico
    Iwanaga, Takashi
    Al-Ahmad, Mona
    Larenas-Linnemann, Desiree
    Kuna, Piotr
    Fonseca, Joao A.
    Al-Lehebi, Riyad
    Rhee, Chin Kook
    Perez-de-Llano, Luis
    Perng Steve, Diahn-Warng
    Mahboub, Bassam
    Wang, Eileen
    Goh, Celine
    Lyu, Juntao
    Newell, Anthony
    Alacqua, Marianna
    Belevskiy, Andrey S.
    Bhutani, Mohit
    Bjermer, Leif
    Bjornsdottir, Unnur
    Bourdin, Arnaud
    von Boulow, Anna
    Busby, John
    Canonica, Giorgio Walter
    Cosio, Borja G.
    Dorscheid, Delbert R.
    Munoz-Esquerre, Mariana
    FitzGerald, J. Mark
    Gil, Esther Garcia
    Gibson, Peter G.
    Heaney, Liam G.
    Hew, Mark
    Hilberg, Ole
    Hoyte, Flavia
    ALLERGY, 2023, 78 (07) : 1934 - 1948
  • [2] Anti-IgE or Anti-IL5: That Is the Question
    Israel, Elliot
    Panettieri, Reynold A., Jr.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2018, 6 (03): : 782 - 784
  • [3] Treating asthma with anti-IgE or anti-IL5
    Lötvall, J
    Pullerits, T
    CURRENT PHARMACEUTICAL DESIGN, 1999, 5 (10) : 757 - 770
  • [4] REAL-WORLD EFFECTIVENESS OF ANTI-IL-5/5R THERAPIES IN SEVERE ATOPIC EOSINOPHILIC ASTHMATICS ELIGIBLE FOR ANTI-IGE THERAPY
    Jackson, D. J.
    Kavanagh, J.
    Roxas, C.
    D'Ancona, G.
    Green, L.
    Thomson, L.
    Fernandes, M.
    Dhariwal, J.
    Nanzer, A. M.
    Kent, B. D.
    THORAX, 2019, 74 : A137 - A138
  • [5] ANTI-IGE AND ANTI-IL5 THERAPY FOR EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
    Solans-Laque, Roser
    Fonseca, Eva
    Luis Callejas-Rubio, Jose
    Martinez-Zapico, Aleida
    Solanich, Xavier
    Miguel Lopez-Dupla, Jesu
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 812 - 813
  • [6] Worldwide Characterization of Severe Asthma Patients Eligible for Both Anti-IL5 and Anti-IgE: Data from the International Severe Asthma Registry (ISAR)
    Sadatsafavi, M.
    Murray, R.
    Ali, N.
    Trung, T.
    Price, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [7] Real World Effectiveness of Anti-IL-5/5R Therapies Is Independent of Co-Eligibility for Anti-IgE Therapy
    Hearn, A.
    Hug, D.
    Somani, Z. A.
    Kavanagh, J.
    D'Ancona, G.
    Fernandes, M.
    Green, L.
    Roxas, C.
    Thomson, L.
    Kent, B. D.
    Dhariwal, J.
    Nanzer, A.
    Jackson, D. J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [8] Real world effectiveness of anti-IL-5/5R therapies is independent of co-eligibility for anti-IgE therapy
    Hearn, Andrew P.
    Hug, Oliver D.
    Somani, Ziana A.
    Kavanagh, Joanne
    d'Ancona, Grainne
    Roxas, Cris
    Green, Linda
    Thomson, Louise
    Fernandes, Mariana
    Kent, Brian D.
    Dhariwal, Jaideep
    Nanzer, Alexandra M.
    Jackson, David J.
    EUROPEAN RESPIRATORY JOURNAL, 2021, 57 (06)
  • [9] Effectiveness of anti-IgE and anti-IL-5 treatment in step 5 asthma patients.
    Saji, Junko
    Muraoka, Hiromi
    Nishimoto, Eriko
    Matsuzawa, Shin
    Okamoto, Mariko
    Inoue, Teppei
    Handa, Hiroshi
    Nishine, Hiroki
    Inoue, Takeo
    Miyazawa, Teruomi
    Mineshita, Masamichi
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [10] Real-life biomarker response to anti-IL5 and anti-IgE therapies in severe asthma patients
    Burkill, S.
    Porsbjerg, C. M.
    Bourdin, A.
    Tran, T. N.
    Martin, N.
    Katial, R.
    Barker, P.
    Wechsler, M. E.
    Maspero, J.
    Bosnic-Anticevich, S.
    Chung, L. P.
    Katsoulotos, G.
    Christoff, G. C.
    Popov, T. A.
    Sadatsafavi, M.
    Torres-Duque, C. A.
    Ulrik, C.
    Assing, K. Dahl
    Hansen, S.
    Altraja, A.
    Lehtimaki, L. A.
    Papadopoulos, N. G.
    Kostikas, K.
    Salvi, S.
    Costello, R. W.
    Francesca, P.
    Iwanaga, T.
    Rhee, C. K.
    Al-Ahmad, M.
    Larenas-Linnemann, D.
    Fonseca, J. A.
    Amaral, R.
    Alving, K.
    Al-Lehebi, R.
    De-Llano, L. Perez
    Kirenga, B.
    Tsai, M.
    Mahboub, B.
    Pfeffer, P. E.
    Henley, W.
    Liu, Y.
    Lyu, J.
    Goh, C.
    Uthaman, T.
    Price, D.
    Townend, J.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
12345